EMA approves label extension for Novartis’ Exjade
This article was originally published in Scrip
The European Medicines Agency has approved a label extension for Novartis' iron overload treatment Exjade (deferasirox), making the drug available to patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.